GRDX vs CLIR Comparison

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.